The Food and Drug Administration (FDA) today approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma and venous or fingerstick whole blood specimens. Approved for use as an aid in the diagnosis of HIV-1 and HIV-2 infection, the Alere Determine HIV-1/2 Ag/Ab Combo test is also the first FDA-approved test that independently distinguishes results for HIV-1 p24 antigen and HIV antibodies in a single test.
The test can be used by trained professionals in outreach settings to identify HIV-infected individuals who might not be able to be tested in traditional health care settings. The test does not distinguish between antibodies to HIV-1 and HIV-2, and is not intended to be used for screening of blood donors.
Detection of HIV-1 antigen permits earlier detection of HIV-1 infection than is possible by testing for HIV-1 antibodies alone. The test, can distinguish acute HIV-1 infection from established HIV-1 infection when the blood specimen is positive for HIV-1 p24 antigen but is negative for HIV-1 and HIV-2 antibodies.
“This test helps diagnose HIV infection at an earlier time in outreach settings, allowing individuals to seek medical care sooner,” says Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research. “Earlier diagnosis may also help to reduce additional HIV transmission.”
HIV infection can result in the development of Acquired Immune Deficiency Syndrome, or AIDS. HIV damages the body’s defense mechanisms by destroying specific blood cells, called CD4+ T cells, which are crucial to helping the body fight diseases. Two types of HIV have been identified, HIV-1 and HIV-2. HIV-1 is responsible for most HIV infections throughout the world. HIV-2 is found primarily in West Africa; however, cases of HIV-2 infection have been reported in North America and Europe.
The Centers for Disease Control and Prevention (CDC) estimates that each year approximately 50,000 people are infected with HIV in the United States. Of the more than 1 million people living with HIV in the United States, approximately 20 percent of those people have not been diagnosed.
The Alere Determine HIV-1/2 Ag/Ab Combo test is manufactured by Orgenics, Ltd. (an Alere, Inc. company) of Yavne, Israel.
FDA Approves First Rapid Diagnostic Test to Detect HIV-1 Antigen and HIV-1/2 Antibodies
Posted in News, Food And Drug Administration (FDA), Rapid Diagnostics, Hiv Infection, Human Immunodeficiency Virus (HIV), Antibodies, Antigens
- New Antibiotic Could Provide Single-Dose Option
- Genetic Evidence for Single-Bacteria Cause of Sepsis Identified for the First Time
- SGNA Issues Position Statement on Reuse of Single-Use Critical Medical Devices
- Reprocessing Hemodynamic Single-Use Devices
- Single-Dose, Needle-Free Ebola Vaccine Provides Long-Term Protection in Macaques
- SGNA Offers Safety Steps to Guard Against CRE Transmission Through ERCP Procedures
- Researchers Study Transmission of Pathogens During 'Beer Pong' Game
- AOHP Seeks Survey Participants to Analyze Blood Exposures Among Healthcare Workers
- 2014 John M. Eisenberg Patient Safety and Quality Award Recipients are Announced
- Simulating the Potential Spread of Measles